Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Dont wait to find out after the damage has been done
The experiment was terminated on day 124 post-injection based on humane endpoint considerations, and mice were sacrificed at this time point for subsequent analyses
Preliminary findings from Virtas book of business indicate its prescribing solution drove transformative health outcomes and immediate business impact, including: Substantial reduction in GLP-1 utilization and corresponding costs Responsible Prescribing prevents ongoing GLP-1 use by over 50% among current GLP-1 users, lowering costs for payers
This recommendation was developed following 6 cases of non-fatal aspiration in fasted patients taking GLP-1 RAs, and is aimed at reducing the risk of the much-feared pulmonary aspiration seen in unfasted patients with an unprotected airway
Weight loss injections like semaglutide, tirzepatide, and liraglutide do not fall into these high-risk categories
Bio 2021, 2 (5), 14151429
